Journament

Keyword Connections - gene therapy Keywords

Connection Type	Connection
Journals	Scientific reports The Analyst current pharmaceutical biotechnology Advanced drug delivery reviews acs nano nanomedicine (london, england) journal of clinical medicine Environmental science & technology nanoscale research letters saudi medical journal Neuro-Oncology expert opinion on therapeutic targets Journal of molecular biology Journal of Virology drug delivery european journal of pharmaceutics and biopharmaceutics : official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik ev Current topics in medicinal chemistry molecular biotechnology experimental neurology laboratory investigation; a journal of technical methods and pathology Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis medical sciences (basel, switzerland) journal of molecular and cellular cardiology Annals of hematology
Research Groups	No Research Group Connected
Bibliographies	[1] Gene therapy for hemophilia: Progress to date and challenges moving forward. [2] AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. [3] The Positive Fate of Biochar Addition to Soil in the Degradation of PHBV-Silver Nanoparticle Composites. [4] A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). [5] Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study. [6] Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs. [7] Engineering anisotropic cardiac monolayers on microelectrode arrays for non-invasive analyses of electrophysiological properties. [8] Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. [9] Impact of nutritional stress on the honeybee colony health. [10] Knowledge and practices of dentists regarding MERS-CoV. A cross-sectional survey in Saudi Arabia. [11] Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization. [12] Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies. [13] Pigs with δ-sarcoglycan deficiency exhibit traits of genetic cardiomyopathy. [14] Nucleofection of phiC31 Integrase Protein Mediates Sequence-Specific Genomic Integration in Human Cells. [15] foamy virus vectors for hiv gene therapy [16] cell and gene therapy approaches for cardiac vascularization [17] antitumor cell-complex vaccines employing genetically modified tumor cells and fibroblasts [18] minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type ia [19] adeno-associated viral vector delivered rnai for gene therapy of sod1 amyotrophic lateral sclerosis [20] progress in gene therapy [21] gene therapy for the treatment of parkinson’s disease: the nature of the biologics expands the future indications [22] folate-conjugated polyspermine for lung cancer–targeted gene therapy [23] mutational analysis of dbd*-a unique antileukemic gene sequence [24] the interplay of post-translational modification and gene therapy [25] non-clinical safety and efficacy of an aav2/8 vector administered intravenously for treatment of mucopolysaccharidosis type vi [26] editorial: gene therapy for the central and peripheral nervous system [27] non-primate lentiviral vectors and their applications in gene therapy for ocular disorders [28] highly branched poly(5-amino-1-pentanol-co-1,4-butanediol diacrylate) for high performance gene transfection [29] gene therapy in glaucoma-part 2: genetic etiology and gene mapping [30] full-length dysferlin transfer by the hyperactive sleeping beauty transposase restores dysferlin-deficient muscle [31] integrin activation: implications for axon regeneration [32] evaluating efficiencies of dual aav approaches for retinal targeting [33] emerging issues in aav-mediated in vivo gene therapy [34] optimization of a neural stem-cell-mediated carboxylesterase/irinotecan gene therapy for metastatic neuroblastoma [35] experimental gene therapy with serine-histogranin and endomorphin 1 for the treatment of chronic neuropathic pain [36] transient expression of an ledgf/p75 chimera retargets lentivector integration and functionally rescues in a model for x-cgd [37] terapia génica con citocinas contra cáncer cervicouterino gene therapy with cytokines against cervical cancer [38] autoimmune dysregulation and purine metabolism in adenosine deaminase (ada)-deficiency [39] hiv, leukemia, and new horizons in molecular therapy [40] platelet gene therapy promotes targeted peripheral tolerance by clonal deletion and induction of antigen-specific regulatory t cells [41] virus wars: using one virus to block the spread of another [42] dna ministrings: highly safe and effective gene delivery vectors [43] efficient restoration of the dystrophin gene reading frame and protein structure in dmd myoblasts using the cindel method [44] construcción de un vector de expresión derivado de virus adenoasociados para corregir in vitro el defecto genético de la enfermedad de morquio a [45] potential of caveolae in the therapy of cardiovascular and neurological diseases [46] genetically engineered multilineage-differentiating stress-enduring cells as cellular vehicles against malignant gliomas [47] improving left ventricular myocardial function after myocardial infarction [48] the challenge of vector development in gene therapy [49] aav-mediated gene supplementation therapy in achromatopsia type 2: preclinical data on therapeutic time window and long-term effects [50] Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector [51] Gene-activated fat grafts for the repair of spinal cord injury: a pilot study [52] Gene targeting in ischemic heart disease and failure: Translational and clinical studies [53] Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND. [54] Determination of the activity of uracil-DNA glycosylase by using two-tailed reverse transcription PCR and gold nanoparticle-mediated silver nanocluster fluorescence: a new method for gene therapy-related enzyme detection [55] Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada. [56] Enhanced regeneration and reinnervation following timed GDNF gene therapy in a cervical ventral root avulsion. [57] ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology [58] Immuno-Oncology - The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets [59] Polysaccharide-coated magnetic nanoparticles for imaging and gene therapy [60] Erratum: Correction to Simultaneous Diagnosis and Gene Therapy of Immuno-Rejection in Rat Allogeneic Heart Transplantation Model Using a T-Cell-Targeted Theranostic Nanosystem (ACS nano (2012) 6 12 (10646-10657)) [61] Gene therapy for hemophilia: Progress to date and challenges moving forward. [62] Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. [63] Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease. [64] Emerging patent landscape for non-viral vectors used for gene therapy. [65] Chemogenetics a robust approach to pharmacology and gene therapy [66] Will airway gene therapy for cystic fibrosis improve lung function? New imaging technologies can help us find out. [67] cationic polyene phospholipids as dna carriers for ocular gene therapy [68] towards routine manufacturing of gene therapy drugs [69] cutting-edge trends on regenerative therapy: induced embryonic and pluripotential stem cells, angiogenic growth factor and gene therapy [70] foamy virus vectors for hiv gene therapy [71] cell and gene therapy approaches for cardiac vascularization [72] adeno-associated viral vector delivered rnai for gene therapy of sod1 amyotrophic lateral sclerosis [73] intricacies for posttranslational tumor-targeted cytokine gene therapy [74] progress in gene therapy [75] ocular and systemic safety of a recombinant aav8 vector for x-linked retinoschisis gene therapy: glp studies in rabbits and rs1-ko mice [76] gene therapy for the treatment of parkinson’s disease: the nature of the biologics expands the future indications [77] folate-conjugated polyspermine for lung cancer–targeted gene therapy [78] the interplay of post-translational modification and gene therapy [79] gene therapy in medicine [80] clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives [81] editorial: gene therapy for the central and peripheral nervous system [82] zarogouldis, p., et al., vectors for inhaled gene therapy in lung cancer. application for nano oncology and safety of bio nanotechnology. int. j. mol. sci. 2012, 13, 10828-10862 [83] current challenges and future directions in recombinant aav-mediated gene therapy of duchenne muscular dystrophy [84] non-primate lentiviral vectors and their applications in gene therapy for ocular disorders [85] manufacturing of acmnpv baculovirus vectors to enable gene therapy trials [86] gene therapy in glaucoma-part 2: genetic etiology and gene mapping [87] emerging issues in aav-mediated in vivo gene therapy [88] optimization of a neural stem-cell-mediated carboxylesterase/irinotecan gene therapy for metastatic neuroblastoma [89] bacteriophage-derived vectors for targeted cancer gene therapy [90] experimental gene therapy with serine-histogranin and endomorphin 1 for the treatment of chronic neuropathic pain [91] connexin 43 gene therapy delivered by polymer-modified salmonella in murine tumor models [92] terapia génica con citocinas contra cáncer cervicouterino gene therapy with cytokines against cervical cancer [93] platelet gene therapy promotes targeted peripheral tolerance by clonal deletion and induction of antigen-specific regulatory t cells [94] the relationship between the antitumor effect of the il-12 gene therapy and the expression of th1 cytokines in an hpv16-positive murine tumor model [95] a double-switch cell fusion-inducible transgene expression system for neural stem cell-based antiglioma gene therapy [96] accelerated wound healing: harnessing the power of platelets, biomaterials, stem cells and gene therapy [97] gene therapy and its approaches in the treatment of oral cancer – a review [98] commentary: gene therapy: a promising approach for neuroprotection in parkinson's disease? [99] episomal nonviral gene therapy vectors slow progression of atherosclerosis in a model of familial hypercholesterolemia [100] novel viral vector systems for gene therapy [101] experimental study of local inner ear gene therapy for controlling autoimmune sensorineural hearing loss